EPIX Pharmaceuticals EPIX Pharmaceuticals
  • Corporate Profile
  • Management
  • Board of Directors
  • Strategic Alliances and Partnering
  • Contact and Directions

Frederick Frank
Chairman of the Board

In addition to serving as the Chairman of the Board of EPIX, Mr. Frank is Vice Chairman of Peter J. Solomon Company (PJSC), and on the board of directors of Landec Corporation, the Institute for Systems Biology, Pharmaceutical Product Development, Inc. and PDL BioPharama, Inc. He is Chairman of the National Genetics Foundation, and a member of the advisory boards of the Yale School of Organization and Management, the Harvard School of Public Health, and the Massachusetts Institute of Technology Center for Biomedical Innovation. Mr. Frank previously served as Vice Chairman of Barclays Capital. Prior to his position at Barclays Capital, Mr. Frank was a Vice Chairman and Director of Lehman Brothers. Before joining Lehman Brothers as a Partner in October 1969, Mr. Frank was co-director of research, as well as Vice President and Director, of Smith, Barney & Co. Inc. He is a Chartered Financial Analyst, a member of The New York Society of Security Analysts and a past president of the Chemical Processing Industry Analysts. Mr. Frank holds a B.A. from Yale University and an M.B.A from the Stanford Graduate School of Business.

Elkan Gamzu, Ph.D.
President and Chief Executive Officer, Epix Pharmaceuticals

Dr. Gamzu joined EPIX in July 2008. Dr. Gamzu is a Principal of enERGetics Biopharmaceutical Consultancy, LLC, and was a founding partner of BioPharmAnalysis, LLC. From February 26, 2007 until January 3, 2008, Dr. Gamzu was the Chief Executive Officer of Pharmos Corporation, and from March 2005 until March 2006, Dr. Gamzu was Acting Head of Clinical Development of Hypnion, Inc. From December 1, 2004 until February 24, 2005, Dr. Gamzu was the interim CEO of XTL Biopharmaceuticals, Ltd., and from 2001 until 2002, Dr. Gamzu was Vice President of Product Management Leadership for Millennium Pharmaceuticals, Inc. Dr. Gamzu also served as President and Chief Executive Officer of Cambridge Neuroscience, Inc. from 1994 until 1998, and as President and Chief Operating Officer and Vice President of Development for Cambridge Neuroscience, Inc. from 1989 to 1994. Previously, Dr. Gamzu held a variety of senior positions with Warner-Lambert and Hoffmann-La Roche, Inc. Dr. Gamzu is a graduate of Hebrew University in Jerusalem, and has M.A. and Ph.D. degrees in experimental and physiological psychology from the University of Pennsylvania.

Michael Gilman, Ph.D.

Dr. Gilman was most recently Executive Vice President, Research at Biogen Idec. He joined Biogen in 1999 as Director of Molecular Biology and became head of research at Biogen in 2000. Dr. Gilman was Executive Vice President and Chief Scientific Officer of ARIAD Pharmaceuticals from 1995 to 2000. Prior to that, Dr. Gilman spent eight years on the scientific staff of Cold Spring Harbor Laboratory in New York, where his research focused on mechanism of signal transduction and gene regulation. Dr. Gilman holds a Ph.D. in Biochemistry from University of California, Berkeley, and a S.B. in Life Sciences from Massachusetts Institute of Technology.

Mark Leuchtenberger
President and Chief Executive Officer, Targanta Therapeutics Inc.

Mr. Leuchtenberger became President and Chief Executive Officer of Targanta Therapeutics, a privately held NDA stage antibiotics company, in 2006. Mr. Leuchtenberger joined Targanta from Therion Biologics Corporation, a privately held cancer vaccine company, where he served as President and Chief Executive Officer from 2002 to 2006. Under his leadership, Therion filed its first IND, progressed through Phase 3 trials, completed the buildup of its commercial manufacturing capabilities, and raised over $120 million in three rounds of private financings. Prior to joining Therion in 2002, Mr. Leuchtenberger spent 11 years at Biogen, Inc., where he led the development and launch of Avonex and ran North American and international commercial operations. Prior to Biogen, he was a consultant at Bain & Company specializing in healthcare. Mr. Leuchtenberger also serves on boards for the Massachusetts Biotechnology Council, Beth Israel Deaconess Medical Center and Wake Forest University.

Gregory D. Phelps
Chairman, President and Chief Executive Officer, RenaMed Biologics, Inc.

Mr. Phelps is the Chairman of the Board, President, and Chief Executive Officer of RenaMed Biologics, Inc., a biotechnology company developing therapeutic products. He has previously held positions of Chief Executive Officer of Ardais Corporation, Viagene, Inc. and ZymoGenetics, Inc. He has also served as Vice Chairman of Dyax Corporation, Executive Vice President of Genzyme Corporation and Vice President of Baxter Travenol Laboratories, Inc. (now Baxter Healthcare).

Ian F. Smith, CPA, ACA
Senior Vice President and Chief Financial Officer, Vertex Pharmaceuticals Incorporated

Mr. Smith is Senior Vice President and CFO of Vertex Pharmaceuticals Inc., a publicly traded biotechnology company. Prior to joining Vertex, Mr. Smith was a Partner with Ernst & Young LLP, where he served as a Partner in the Life Science and Technology practice. Mr. Smith received a B.A. with honors in accounting and finance from Manchester Metropolitan University, U.K., is a member of the American Institute of Certified Public Accountants and is a Chartered Accountant of England and Wales.